Not long after retiring from GlaxoSmithKline, where he led R&D and then the vaccines group, Moncef Slaoui started signing up for a variety of biotech boards. There was a seat at the table for SutroVax, mRNA player Moderna as well as the public outfit Intellia $NTLA, one of a handful of CRISPR/Ca9 gene editing startups dominating the field.
Then, earlier today, he was suddenly gone.
In an SEC filing Intellia noted that Slaoui had abruptly departed on Monday “due to a conflict of interest.”
That’s it. There was no explanation of what conflict had arisen, just that he was off the board. The Boston Business Journal first reported the sudden exit.
Slaoui was known for embracing a slate of potential breakthrough drugs while he was head of R&D, though the company wasn’t able to capitalize on any of them. The blockbuster drug candidates ultimately failed, though GSK has had some big successes in HIV and vaccines. Now GSK is trying to revamp its pipeline, looking to kickstart an otherwise lackluster development group.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription